Botanix Pharmaceuticals reports accelerating Sofdra adoption in Q4 FY26, with prescriptions up 25% to 33,358 and a June monthly peak of 12,895, alongside $46.7 million in gross sales and a $10.1 million net revenue, aided by a improving gross-to-net yield of 22%. The company is trimming costs, expanding its API supplier base, fortifying its IP position, and narrowing operating cash burn as it strengthens its US market focus and dual US-Australia business footprint to support sustainable growth.
